Real World Teclistamab Results for Relapsed Refractory Myeloma Patients | Meera Mohan, MD | ASH 2023

Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023Подробнее

Long-term follow-up of real-world teclistamab therapy for R/R multiple myelomaПодробнее

Bispecific Antibody Therapy in Relapsed/Refractory Myeloma | Meera Mohan, MD, MS, FACP | ASCO 2023Подробнее

Evaluating Teclistamab in Relapsed and/or Refractory Multiple MyelomaПодробнее

Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMMПодробнее

Real-world study determining the safety and efficacy of teclistamab in R/R multiple myelomaПодробнее

2-year follow-up of MajesTEC-1: teclistamab in R/R multiple myelomaПодробнее

Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022Подробнее

Teclistamab for RRMM: Long term follow up data from MajesTEC-1Подробнее

The recent FDA approval of teclistamab for R/R multiple myelomaПодробнее

MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myelomaПодробнее

Panel Discusses Use of Bispecifics to Treat Relapsed/Refractory Myeloma, Toxicity ConsiderationsПодробнее

Teclistamab for multiple myeloma in US hospitals: real-world data analysisПодробнее

Real-world outcomes of teclistamab treatment in R/R multiple myelomaПодробнее

Updates on Phase 1b TRIMM-2 Study Results of Teclistamab + Daratumumab Presented at EHA 2022Подробнее

Talquetamab in BCMA-Exposed Relapsed/Refractory Multiple #Myeloma | Hira Shaikh, MD | #ASH24Подробнее

Updated results of a phase 1, first-in-human study of talquetamab in relapsed refractory MMПодробнее

The value of teclistamab in R/R myeloma & strategies to mitigate toxicitiesПодробнее